Avedro, a global ophthalmic medical device and pharmaceutical company, has expanded its portfolio of proprietary riboflavin formulations for corneal collagen cross-linking.

The new formulations when used in conjunction with Avedro’s KXL System reduce the time required to perform cross-linking and in some applications improve cross-linking utility, said the company.

Avedro president and CEO David Muller said Avedro’s KXL System for accelerated cross-linking is available in over 50 countries, and has been used in combination with the company’s VibeX riboflavin to treat tens of thousands of eyes world-wide.

"Our research team has done an excellent job expanding the available riboflavins to meet the specific needs of our user physicians and their patients," Muller added.

Avedro’s family of riboflavin products is commercially available in countries recognizing the CE Mark, and includesVibeX, VibeX Rapid, VibeX Xtra, and ParaCel for trans-epithelial cross-linking.

The Istituto Laser Microchirurgia Oculare (ILMO) director Roberto Pinelli said, "When using ParaCel in combination with Avedro’s KXL System, I am able to treat my keratoconic patients in a much shorter time, without the post-operative discomfort associated with removal of the epithelium."

Avedro is currently sponsoring on-going Phase III cross-linking clinical trials in the US.